This systematic review with meta-analysis sought to compare the efficacy and safety of intracoronary (IC) vs. intravenous (IV) administration of glycoprotein (GP) IIb/IIIa receptor inhibitors on clinical outcomes following percutaneous coronary intervention in patients with acute coronary syndromes (ST-segment elevation myocardial infarction or non-ST-segment-elevation acute coronary syndrome).
INTRODUCTION
Ischaemic heart disease is usually caused by thrombotic occlusions of major epicardial coronary arteries in the absence of sufficient collateral blood supply. Early, complete, and sustained reperfusion by prompt recanalisation of infarct related arteries by utilisation of percutaneous coronary intervention (PCI), or alternatively thrombolytic therapy, has been shown to decrease infarct size, preserve ventricular function, improve contractility and reperfusion, and reduce morbidity and mortality [1] . Also, platelets may play an important role in the thrombotic and inflammatory cascades in coronary atherosclerosis [1] . It has been shown that the extent of inhibition of platelet aggregation depends on some factors, such as clinical presentation, antiplatelet agents used, and dose of antiplatelet agents administered [2] . Glycoprotein (GP) IIb/IIIa is an integrin complex on platelets, which represents a receptor for fibrinogen and von-Willebrand factor responsible for platelet activation [2] [3] [4] . GP IIb/IIIa inhibitors, such as abciximab, eptifibatide, and tirofiban, are antiplatelet agents, which are often used in combination with angioplasty with or without stent placement in the treatment of patients with unstable angina or myocardial infarction (MI) [2] [3] [4] [5] . Administration of GP IIb/IIIa inhibitors may result in high local concentration, which may lead to increased levels of platelet GP IIb/GPIIIa receptor occupancy, destabilisation of platelet aggregates, and promotion of thrombus disaggregation in epicardial arteries and microvasculature [3] . This systematic review with meta-analysis sought to determine the strength of evidence for comparing the efficacy and safety of GP IIb/IIIa inhibitors administrated either as an intracoronary bolus or as an intravenous bolus in patients with acute coronary syndromes (ACS) undergoing PCI.
METHODS

Literature search
A comprehensive literature search was conducted in major electronic databases (Medline/PubMed, Embase, Elsevier, web of knowledge, Sciences online database, and Google Scholar) from their inception until 15 th July 2014 to identify randomised controlled trials (RCT) that reported on the comparison of effects of GP IIb/IIIa inhibitors administrated either as an intracoronary (IC) bolus or as an intravenous (IV) bolus on clinical outcomes in patients with ACS undergoing PCI. Predefined search terms were: "glycoprotein IIb/IIIa inhibitors", "abciximab", "eptifibatide", "tirofiban", "GP IIb/IIIa inhibitors", "glycoprotein IIb/IIIa antagonist" and "intracoronary", "intravenous", "bolus", and "myocardial infarction", "MI", "ST-segment myocardial infarction", "STEMI", "non-STEMI", "acute coronary syndrome ", and "percutaneous coronary intervention", "PCI", and "angioplasty". There were no language limitations. All retrieved reference lists of included RCTs were also reviewed to determine additional studies not indexed in common databases. Studies were included into the analysis when they met the following criteria: 1) RCT; 2) reporting at least one of the outcomes of interest, including: left ventricular ejection fraction (LVEF), thrombolysis in myocardial infarction (TIMI) score, re-MI, heart failure (HF), stent thrombosis, bleeding, target vessel revascularisation (TVR), and mortality. In addition, abstracts without peer-review publications of manuscripts, duplicate reports, and ongoing RCTs were not included.
Data extraction and outcome measures
Two investigators (S.A-H-S and A.S) extracted data independently, and discrepancies were resolved via a consensus standardised abstraction checklist used for recording data in each study. Data retrieved from trials included the author's name, country, study design, details of therapeutic regimens, clinical scenario, sample size, follow-up duration, mean age, and gender, and clinical outcomes. For exploration of heterogeneity among trials, a subgroup analysis of disparities in patients' characteristics was performed for 
Primary and secondary end-points
The primary end-points were TVR and mortality, whereas the secondary end-points were mean changes of LVEF, incidence of TIMI 3 flow, re-MI, major bleeding, stent thrombosis, and HF.
Definitions of end-points
Target vessel revascularisation was defined as ischaemia-driven revascularisation of the infarct-related artery with PCI and coronary artery bypass graft. Re-MI was defined as recurrent symptoms suggestive of ischaemia with ST-segment elevation and/or elevation of the levels of cardiac markers. LVEF was assessed during hospital stay by echocardiography. TIMI 0 flow (no perfusion) refers to the absence of any antegrade flow beyond the occlusion; TIMI 1 flow (penetration without perfusion) is a faint antegrade flow beyond the occlusion, with incomplete filling of the distal coronary bed; TIMI 2 flow (partial perfusion) is a delayed or sluggish antegrade flow with complete filling of the distal territory; and TIMI 3 flow (complete perfusion) is a normal flow that fills the distal coronary bed completely. Major bleeding was defined as that which occurred during the hospitalisation, using TIMI criteria. Mortality was considered to be cardiac unless a non-cardiac cause of death could be established.
Statistical analysis, publication bias, and quality assessment All data were analysed by STATA version 11.0 utilising METAN and METABIAS modules. The effect sizes measured were odds ratio (OR) with 95% confidence interval (95% CI) for categorical variables. For non-categorical data the weighted mean difference (WMD) with 95% CI was used for calculating differences in LVEF between intervention and control groups. OR < 1 favoured intravenous bolus administration and OR > 1 favoured intracoronary bolus administration. RCTs with no events in the two arms were discarded from pooled analysis. Forest plots were created for each outcome. A value of p < 0.1 for Q test or I 2 > 50% indicated significant heterogeneity among studies. Heterogeneity among trials was accounted for by applying a random effect model when indicated. Subgroup analysis was performed to further identify the possible sources of heterogeneity, and a p value of < 0.1 was accepted as significant. Sensitivity analysis was performed to evaluate the robustness of the result with the random-effects method. The presence of publication bias was evaluated using the Begg and Egger tests. Quality assessment of RCTs was performed by using the Jadad score. The Jadad score assesses three items, including randomisation (0-2 points), blinding of study (0-2 points), and withdrawals and dropouts (0-1 points). Higher scores indicated better reporting ("high" quality: 5; "good" quality: 3-4; "poor" quality: 0-2). Results were considered statistically significant at p < 0.05.
RESULTS
Literature search strategy and included trials
Literature search retrieved 1006 studies from screened databases, of which 835 (83%) were excluded after initial review. Of 171 primarily included studies, 153 were excluded after detailed evaluation due to insufficient reporting on end-points of interest. The final analysis included 18 RCTs (5812 patients).
Study characteristics, effect measures, and clinical outcomes
Primary end-points Target vessel revascularisation. A total of 2969 patients were included from 10 RCTs that reported data on the incidence of TVR. The patient population of RCTs ranged from 41 to 1005 patients, with a mean age of 63.07 years, and 72.7% were males (Table 1) . From all cases, 1767 cases were allocated to the IV group and 1202 cases to the IC group (Table 1) . One in ten comparisons did not present any postoperative death events in two comparative arms; therefore, the remaining nine RCTs (2928 cases) were used to perform the meta-analysis. The overall incidence of TVR was 6.5%, ranging from 0.8% to 24.7%. TVR occurred in 6.69% in the IV group and 6.35% in the IC group (Table 2) . Pooled analysis indicated that the incidence of TVR was similar between patients who received IV or IC bolus administration with an OR of 1.14 (95% CI 0.83-1.56; p = 0.4) using a fixed model (Fig. 1) . No significant heterogeneity was observed among RCTs (c 2 = 8.53, I 2 = 6.2%, p = 0.3). Mortality. Seventeen RCTs (5763 patients) reported data on death. Mortality occurred in 2.9% (89 cases) in the IV group and 3.4% (91 patients) in the IC group. Three of 17 comparisons did not present any postoperative death events in two comparative arms; thus the remaining 14 RCTs (5632 cases) were used to perform the meta-analysis. Patients had a mean age of 62.3 years, and 75% were males (Table 1) . Pooled treatment effect analysis revealed that IV and IC bolus administrations have similar effects on the incidence of mortality with an OR of 1.18 (95% CI 0.87-1.6; p = 0.2) using a fixed model (Fig. 2) . No heterogeneity was observed among RCTs (c 2 = 9.98, I 2 = 0.0%, p = 0.6).
Secondary end-points Left ventricular ejection fraction. A total of 400 patients were included from five RCTs that reported data on LVEF. Patient populations of RCTs ranged from 20 to 154 patients, with a mean age of 63.4 years, and 78.1% were males (Table 1) . From all patients, 201 cases were allocated to the IV group and 202 cases to the IC group (Table 1) . Mean LVEF for all trials was 51.9 ± 8.4 with 50.6 ± 8.1 for IV and 53.3 ± 8.6 for the IC group (Table 2 ). Pooled analysis with random effect model revealed that IC therapy succeeded in significantly increasing LVEF with a WMD of 4.97 (95% CI 3.34-6.60; p = 0.000) (Fig. 3 ). There was a significant heterogeneity among studies (c 2 = 18.28, I 2 = 78.1%, p = 0.00). Subgroup analysis showed that studies with male percentage ≤ 80%, mean age more than 65 years, small-molecule GP IIb/IIIa inhibitors, and follow-up duration less than six months were the main causes for heterogeneity among trials (Table 3 ). Sensitivity analysis reported that significant increase of LVEF following IC administration is not dependent on results of most studies (Table 4) .
Thrombolysis in myocardial infarction score 3 flow. A total of 3695 patients were included from 13 RCTs that reported data on TIMI-score. Patient populations of RCTs ranged from 40 to 2065 patients, with a mean age of 63.1 years, and 75.7% were males (Table 1) . From all cases, 1824 cases were allocated to the IV bolus group and 1871 cases to the IC bolus group (Table 1) . The overall incidence of TIMI-3 was 85.5%: 83.1% in the IV group and 87.9% in the IC group (Table 2) . Pooled treatment effect analysis revealed that IC, compared to IV bolus administration, could significantly increase TIMI-3 flow with an OR of 0.77 (95% CI 0.64-0.92; p = 0.005) using a random model (Fig. 4 ). Significant heterogeneity was observed among RCTs (c 2 = 19.44, I 2 = 38.3%, p = 0.07). Moreover, subgroup analysis was performed for exploring the cause of heterogeneity, and indicated that the studies with male percentage < 80%, age more than 65 years, sample size less than 200 patients, small molecule GP IIb/IIIa inhibitors, and follow-up duration less than six months was significantly different among treatment groups (Table 3) . Begg and Egger tests showed that there was no potential publication bias among RCTs included in the present analysis (Begg test, p = 0.542; Egger test, p = 0.542). Sensitivity analysis showed that significant increase of TIMI-3 flow following IC administration is not dependent on results of any study (Table 4) . 
AE
Re-myocardial infarction. A total of 5080 cases were included from 13 RCTs that reported data on the incidence of re-MI. After discarding three studies with "zero columns" in two comparative arms, a total of 2642 cases were allocated to the IV group and 2262 cases to the IC group. Patients had a mean age of 63.7 years, and 73.7% were males ( Table 1) . The overall incidence of re-MI was 2.12% with a range from 0.86% to 7.5%. Re-MI occurred in 2.38% in the IV group and 1.85% in the IC group (Table 2 ). Pooled analysis reported that IC bolus administration could not decrease the incidence of re-MI when compared to IV application with an OR of 1.259 (95% CI 0.847-1.871; p = 0.2) using a fixed model (Fig. 5) . No significant heterogeneity was observed among RCTs (c 2 = 7.96, I 2 = 0.0%, p = 0.5). Begg and Egger tests showed that there was no potential publication bias among RCTs included (Begg test, p = 0.421; Egger test, p = 0.421).
Major bleeding. A total of 3775 patients were included from 13 RCTs that reported data on the incidence of major bleeding. In fact, two of 13 comparisons did not present any postoperative death events in two comparative arms; therefore, the remaining 11 RCTs (3685 cases) were used to perform the meta-analysis. Patients had a mean age of 63.6 years, and 74.8% were males ( Table 1 ). The overall incidence of major bleeding was 11.72%, accounting for 12.11% in the IV group and 11.34% in the IC group (Table 2 ). Pooled analysis indicated that the occurrence of major bleeding was statistically similar between patients who received IV or IC bolus administration with an OR of 1.067 (95% CI 0.873-1.305; p = 0.5) using a fixed model (Fig. 6) . No significant heterogeneity was observed among RCTs (c 2 = 8.26, I 2 = 0.0%, p = 0.6). Begg and Egger tests showed that there was no potential publication bias among RCTs included. (Begg test, p = 0.625; Egger test, p = 0.625).
Incidence of stent thrombosis. Four RCTs reported data on stent thrombosis. Overall incidence of thrombosis was 1.77%: 2.26% in the IV group and 1.27% in the IC group (Table 2 ). Pooled analysis indicated that both routes of bolus administration have similar effects on the incidence of stent thrombosis, with an OR of 1.728 (95% CI 0.703-4.25; p = 0.2) using a fixed model (Fig. 7) . No significantly heterogeneity was observed among RCTs (c 2 = 2.07, I 2 = 0.0%, p = 0.5). Heart failure. A total of 2334 patients were included from three RCTs that reported data on the incidence of HF. Overall incidence of HF was 3.21%: 4.19% in the IV group and 2.22% in the IC group (Table 2 ). Pooled analysis indicated that IC, compare to IV bolus administration, can significantly decrease the incidence of HF with an OR of 1.927 (95% CI 1.189-3.124; p = 0.008) using a fixed model (Fig. 8) . No significant heterogeneity was observed among RCTs (c 2 = 0.65, I 2 = 0.0%, p = 0.7). Begg and Egger tests showed that there was no potential publication bias among included RCTs (Begg test, p = 0.602; Egger test, p = 0.602). Sensitivity analysis reported that significant decrease of HF following IC administration is not dependent on results of any study (Table 4) . IC -intracoronary; IV -intravenous; LVEF -left ventricular ejection fraction; TIMI -thrombolysis in myocardial infarction; TVR -target vessel revascularisation; MI -myocardial infarction; HF -heart failure; MACE -major adverse cardiovascular events; ND -no data DISCUSSION Ischaemic heart disease is known as the most common cause of morbidity and mortality as well as decrease in quality of life worldwide [22, 23] . Although the formation of atherosclerotic plaques in coronary arteries is a long-term process, genetic and environmental backgrounds, such as hypertension, hyperlipidaemia, and diabetes mellitus, have a strong potential to accelerate that process, resulting in early significant obstructions, 
reduction of blood supply to myocardial tissue, and incidence of MI [22, 23] . Despite several types of pharmacotherapy, such as fibrinolytics and anticoagulants, angioplasty can result in optimal reperfusion. On the other hand, in the presence of simultaneous obstructions in proximal parts of several coronary arteries, or in case of significant stenosis of the left main coronary artery, a coronary artery bypass graft surgery is required [1] . Current guidelines do not recommend routine use of GP IIb/IIIa inhibitors in ACS; however, the IC route may be considered although the IV route should remain the standard of care for administration of GP IIb/IIIa inhibitors [3] . Our findings revealed that GP IIb/IIIa inhibitors injected using the IC route significantly increase the chance of complete perfusion (TIMI 3 flow) compared to IV administration. This can mainly be explained by the high local platelet inhibitor concentration caused by IC injection. Our subgroup analysis also indicated that the IC route had a remarkable preference to the IV route in terms of increasing the incidence of complete perfusion in patients with NSTE-ACS and STEMI, particularly those in older ages. Wu et al. [8] found that IC administration of platelet inhibitors led to a higher rate of complete perfusion; therefore, it might be able to decrease the size of infarcted parts of myocardium. Infarcted myocardium is usually associated with reduced perfusion, decreased ventricular contractility, and subsequently reduced LVEF. Finally, cardiac function can enter a vicious circle with decreasing LVEF, leading to gradually increasing inability of the heart muscle to pump the remaining blood volume, eventually leading to HF. The results of the current study revealed that IC administration of GP IIb/IIIa inhibitors, in comparison with the IV route, could increase LVEF. In addition, the incidence of HF was notably lower in receivers of IC antiplatelets, compared to IV. It can be deduced that IC administration is associated with complete perfusion followed by increased contractility and LVEF, and it may prevent progression from reversible MI to permanent HF. Our subgroup analysis also reported more effective therapeutic response following IC administration of antiplatelets in older ages, but better LVEF was noted in NSTE-ACS and STEMI patients both aged above and below 65 years. According to our findings, the incidence of TVR was similar in both groups. Kubica et al. [24] similarly reported no significant difference in the incidence of TVR between IC and IV GP IIb/IIIa inhibitor receivers. Early recurrent MI or extension of infarction have been clinically recognised for many years as manifested by severe prolonged chest pain WMD -weighted mean differences; rest abbreviations as in Table 2 AE Figure 4 . Forest plot of odds ratio (OR) for treatment with glycoprotein IIb/IIIa inhibitors on incidence of thrombolysis in myocardial infarction score 3 flow; CI -confidence interval; IC -intracoronary; IV -intravenous Figure 5 . Forest plot of odds ratio (OR) for treatment with glycoprotein IIb/IIIa inhibitors on incidence of re-myocardial infarction; CI -confidence interval; IC -intracoronary; IV -intravenous Figure 6 . Forest plot of odds ratio (OR) for treatment with glycoprotein IIb/IIIa inhibitors on incidence of major bleeding; CI -confidence interval; IC -intracoronary; IV -intravenous Figure 7 . Forest plot of odds ratio (OR) for treatment with glycoprotein IIb/IIIa inhibitors on incidence of stent thrombosis; CI -confidence interval; IC -intracoronary; IV -intravenous as well as new ST-T wave abnormalities on electrocardiography [25] . Rupture of atherosclerotic plaques leads to the exposure of collagen and vascular media, resulting in platelet and clotting activation and occlusive thrombus formation [25] . Our results demonstrated that IC or IV administration were not significantly different regarding the incidence of re-MI. Regarding the critical role of platelets in blood clotting, GP IIb/IIIa inhibitors, as antiplatelet drugs, inhibit the connection between fibrinogen and von-Willebrand factor to the activated platelets leading to platelet disaggregation. However, administration of antiplatelet drugs may lead to an increased incidence of haemorrhage compared to placebo. The findings of our study found that the incidence of haemorrhage was not different when administering GP IIb/IIIa inhibitors via IC or IV route. Therefore, based on the results of our study we disagree with the theory that the IC route increases the risk of bleeding due Figure 8 . Forest plot of odds ratio (OR) for treatment with glycoprotein IIb/IIIa inhibitors on incidence of heart failure; CI -confidence interval; IC -intracoronary; IV -intravenous to high local platelet inhibitor concentration. AIDA multicentre trial showed that in patients with STEMI undergoing PCI, IC bolus administration of abciximab did not give any additional benefit compared with standard intravenous bolus administration with respect to the combined primary study end-point death, re-MI, or congestive HF. Since IC abciximab bolus administration was safe and was related to reduced rates of congestive HF [9] . Finally, our study showed that the risk of mortality and incidence of stent thrombosis were not significantly different when administering GP IIb/IIIa inhibitors by either route. However, the primary end-points of this study were not statistically significant; overall, the most appropriate route of administration of GP IIb/IIIa inhibitors appeared to be IC injection, which could increase LVEF and TIMI 3 flow and decrease the incidence of HF.
Limitations of the study This meta-analysis contains several limitations. First, it was a study-level meta-analysis; second, a comparison of different GP IIb/IIIa inhibitors was performed according to the use of various inhibitors in the RCTs included; third, there was a natural lack of available data on end-points assessed in studies included in the meta-analysis; fourth, several minor deviations definitions of end-points might be present; fifth, there is a lack of data on different GP IIb/IIIa inhibitor concentrations after both IC and IV administrations; and sixth, both STEMI and NSTEMI patients were included in the present analysis in order to increase the number of patients analysed; however, no differentiation or sub-group analysis was performed.
CONCLUSIONS
The most appropriate route of administration of GP IIb/IIIa inhibitors for patients with ACS seems to be IC injection, which can increase LVEF and TIMI 3 flow and decrease HF with comparable adverse event rates as using IV injection.
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